Antitumor therapeutic strategies that fundamentally rely on the induction of DNA damage to
eradicate and inhibit the growth of cancer cells are integral approaches to cancer therapy …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …

The principle of synthetic lethality, which refers to the loss of viability resulting from the
disruption of two genes, which, individually, do not cause lethality, has become an attractive …

Homologous recombination and DNA repair are important for genome maintenance.
Genetic variations in essential homologous recombination genes, including BRCA1 and …

Germline BRCA–associated pancreatic ductal adenocarcinoma (gl BRCA PDAC) tumors are
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …

PARP1 mediates poly-ADP-ribosylation of proteins on chromatin in response to different
types of DNA lesions. PARP inhibitors are used for the treatment of BRCA1/2-deficient …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …

Proper repair of DNA damage lesions is essential to maintaining genome integrity and
preventing the development of human diseases, including cancer. Increasing evidence …

Prostate cancer (PC) is the second most common cancer in men worldwide. Due to the large-
scale sequencing efforts, there is currently a better understanding of the genomic landscape …